Results 41 to 50 of about 8,130 (203)

“Ways in which the neonatal Fc-receptor is involved in autoimmunity”

open access: yesJournal of Translational Autoimmunity, 2021
Since the neonatal IgG Fc receptor (FcRn) was discovered, its role has evolved from immunoglobulin recycling and biodistribution to antigen presentation and immune complex routing, bringing it to the center of both humoral and cellular immune responses ...
Juliette Lamamy   +5 more
doaj   +1 more source

Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier

open access: yesmAbs, 2023
The blood-brain barrier (BBB) largely excludes antibodies from entering the central nervous system, thus limiting the potential of therapeutic antibodies to treat conditions such as neurodegenerative diseases and neuro-psychiatric disorders.
Jason Tien   +13 more
doaj   +1 more source

The Recycling and Transcytotic Pathways for IgG Transport by FcRn are Distinct and Display an Inherent Polarity [PDF]

open access: yes, 2012
The Fc receptor FcRn traffics immunoglobulin G (IgG) in both directions across polarized epithelial cells that line mucosal surfaces, contributing to host defense.
Blumberg, Richard Steven   +9 more
core   +1 more source

Tissues Expression, Polymorphisms Identification of FcRn Gene and Its Relationship with Serum Classical Swine Fever Virus Antibody Level in Pigs [PDF]

open access: yesAsian-Australasian Journal of Animal Sciences, 2012
Neonatal Fc receptor (FcRn) gene encodes a receptor that binds the Fc region of monomeric immunoglobulin G (IgG) and is responsible for IgG transport and stabilization.
Liu Yang   +8 more
doaj   +1 more source

Expression of neonatal Fc receptor in the eye [PDF]

open access: yes, 2014
PURPOSE: The neonatal Fc receptor (FcRn) plays a critical role in the homeostasis and degradation of immunoglobulin G (IgG). It mediates the transport of IgG across epithelial cell barriers and recycles IgG in endothelial cells back into the bloodstream.
Christianson, G. J.   +4 more
core   +1 more source

Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions

open access: yesFrontiers in Immunology, 2015
Despite the reasonably long half-life of IgGs, market pressure for higher patient convenience while conserving efficacy continues to drive IgG half-life improvement.
Céline eMonnet   +8 more
doaj   +1 more source

Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas. [PDF]

open access: yes, 2019
Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects worldwide, yet the most effective strategies for preventing virus transmission during pregnancy are unknown.
An, Zhiqiang   +8 more
core   +1 more source

Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn

open access: yesBrain Research, 2013
Monoclonal antibody (mAb) engineering that optimizes binding to receptors present on brain vascular endothelial cells has enabled them to cross through the blood-brain barrier (BBB) and access the brain parenchyma to treat neurological diseases. However, once in the brain the extent to which receptor-mediated reverse transcytosis clears mAb from the ...
Cooper, Philip R.   +7 more
openaire   +2 more sources

Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn) [PDF]

open access: yesJournal of Biological Chemistry, 2006
We describe here the functional implications of an increase in IgG binding to the neonatal Fc receptor. We have defined in a systematic fashion the relationship between enhanced FcRn binding of a humanized anti-respiratory syncytial virus (RSV) monoclonal antibody (MEDI-524) and the corresponding biological consequences in cynomolgus monkeys.
William F, Dall'Acqua   +2 more
openaire   +2 more sources

New roles for Fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer's disease [PDF]

open access: yes, 2014
There are an estimated 18 million Alzheimer's disease (AD) sufferers worldwide and with no disease modifying treatment currently available, development of new therapies represents an enormous unmet clinical need.
Fuller, James P.   +2 more
core   +3 more sources

Home - About - Disclaimer - Privacy